ABOUT XTL BIOPHARMACEUTICALS LTD.
XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the acquisition, development and commercialization of therapeutics for the treatment of neuropathic pain and hepatitis C. XTL is developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment of neuropathic pain. XTL is also developing several novel pre-clinical hepatitis C small molecule inhibitors. XTL also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. XTL is publicly traded on the NASDAQ, London, and Tel-Aviv Stock Exchanges (NASDAQ: XTLB; LSE: XTL; TASE: XTL).
Some of the statements included in this press release, particularly
those anticipating continued undisrupted trading of the Company's ADRs on
NASDAQ or the future cancellation of the Company's Ordinary Shares on the
Official List of the United Kingdom Listing Authority and similar matters,
may be forward-looking statements that involve a number of risks and
uncertainties. For those statements, we claim the protection of the safe
harbor for forward-looking statements contained in the Private Securities
Litigation Reform Act of 1995. Risk factors that could adversely affect our
operations are identified from time to time in our reports filed with the
Securities and Exchange Commission and the London Stock Exchange, including
our annual report on Form 20-F filed with the Securities and Exchange
Commission on March 23, 2007. Any forward-looking statements set forth in
this press release speak only as of the date of this press r
|SOURCE XTL Biopharmaceuticals Ltd|
Copyright©2007 PR Newswire.
All rights reserved